Leaky ship........I smell an announcement, page-4

Looks like shorters in anticipation of a damp squib Half Yearly, followed by extended discussion with FDA, which will take longer than expected and probably conclude around May with the same negative outcome, and then a non-event soft-launch of VivaGel by Aspen in June, and Mundipahrma in one European country by October, just in time for the next AGM, by which time they should be starting to enrol women for "Confirmnatory clinical data" (trials.)

Sorry to be so negative, still holding, just, but not prepared to lose any more opportunities in the meantime while the shorters exploit management's incompetence and lack of transparency (honesty.) Glad I sold most of my SPL holdings at 1.29 on Feb 27 and redeployed the capital (for an approximate return of 20% so far - rather than a further loss of 25%.) I'm sure there'll be plenty of time to jump back in once they pull their finger out - next year maybe. Should be around 80c by then. All IMHO. Not downramping, still love the science, just another disillusioned long time holder and more than happy to be proved wrong.